Veracyte's stock surged 7.73% intraday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations and the company's subsequent upward revision of its full-year outlook.

The diagnostic company reported quarterly earnings of $0.52 per share, beating the consensus estimate of $0.15 by a substantial margin. Revenue for the quarter reached $139.1 million, surpassing estimates and representing a 21% year-over-year increase. Key drivers included a 30% growth in Decipher test revenue and a 21% growth in Afirma test revenue, contributing to a net income rise of 307% to $28.7 million.

Investor sentiment was further bolstered as Veracyte raised its 2026 guidance, increasing its total revenue outlook to a range of $582 million to $592 million and projecting an adjusted EBITDA margin greater than 26%. The positive developments were complemented by analyst action, with Leerink Partners raising its price target on the stock.